Badly implemented electronic systems putting NHS patients at risk
October 24, 2019Business Services
A new report has warned that poorly implemented electronic medication systems in the NHS could potentially lead to fatal medication …
GSK receives wider nod for Zejula as it competes with rival AstraZeneca
October 24, 2019Research and Development
The US FDA has approved GlaxoSmithKline’s Zejula (niraparib) for the use in advanced ovarian, fallopian tube, or primary peritoneal cancer …
Damage control: How will pharma manage the health economic impacts of Brexit?
October 23, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HEOR, brexit, health economics and outcomes research, pharma
When it comes to life sciences and patient outcomes, the UK’s destiny is inextricably tied to its relationship with the …
FDA approves Vertex’s Trikafta in new indication, now potentially covering 90% of cystic fibrosis patients
October 23, 2019Research and Development, Sales and Marketing FDA, Trikafta, Vertex, cystic fibrosis, pharma
The FDA has granted marketing authorisation to Vertex’s Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF), it …
New study shows Prozac no better than placebo in treating autism
October 23, 2019Research and Development
A small study has found that the commonly prescribed medication for kids and teenagers with autism is no more effective …
BMS’ Opdivo+Yervoy+Chemo combo shows superior overall survival in first-line lung cancer
October 23, 2019Research and Development Bristol-Myers Squibb, Cancer, NSCLC, Yervoy, lung cancer, opdivo, pharma
Bristol Myers Squibb has lifted the curtain on new Phase 3 data for its blockbuster immunotherapy Opdivo (nivolumab), showing that …
Biogen aiming for Aducanumab to slow Alzheimer’s progression
October 23, 2019Research and Development
US firm Biogen is hoping for approval to bring about a treatment that could slow the onset of Alzheimer’s disease. …
Takeda acquires investigational coeliac disease therapy
October 23, 2019Research and Development
Takeda has acquired licensing for a first-in-class investigational coeliac disease therapy CNP-101/TAK-101. The Japanese pharma giant now has the rights …
Porton Biopharma signs potential $24m deal to push its intranasal anthrax vaccine into Phase 1 trials
October 22, 2019Manufacturing and Production, Research and Development FDA, Porton Biopharma, anthrax, pharma
Porton Biopharma has signed a modification to its existing agreement with the US National Institute of Health’s National Institute of …
Novo Nordisk opens first Pharmatech branch office in Singapore
October 22, 2019Manufacturing and Production Novo Nordisk, Singapore, pharma
Novo Nordisk has celebrated the launch of a new Pharmatech A/S branch office based in Singapore at a grand opening …
Teva offers massive $23 billion to avoid thousands of lawsuits
October 22, 2019Manufacturing and Production
Israeli drug company Teva has said that it would offer $250 million in cash and a supply of Suboxone, an …
Cancer Research UK announces push for earlier cancer detection
October 22, 2019Manufacturing and Production
Cancer Research UK has embarked on a new international alliance with a plan to develop ‘radical new strategies’ and technologies …
US FDA approves Vertex’s new breakthrough therapy for cystic fibrosis
October 22, 2019Manufacturing and Production
The US FDA has approved Trikafta (elexacaftor/ivacaftor/tezacaftor) – the first triple combination therapy available for patients with most common cystic …
“No deal” Brexit and life sciences: What happens?
October 21, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, Europe, UK, brexit, no deal, no-deal, pharma
Prime Minister Boris Johnson may have agreed a withdrawal agreement with the European Union at the 11th hour, but despite …
FDA approves Alexion’s Ultomiris in atypical haemolytic uremic syndrome for adults and children
October 21, 2019Sales and Marketing Alexion, FDA, Ultomiris, pharma, rare disease
The FDA has moved to expand the existing label for Alexion’s Ultomiris (ravulizumab-cwvz) to include the treatment of atypical haemolytic …
CHMP recommends several drugs for EU market approval
October 21, 2019Sales and Marketing
The EMA’s human medicines committee (CHMP) has recommended seven medicines for approval at its October 2019 meet including MSD’s Ervebo, …
Roche’s Tecentriq/Avastin combo smashes endpoints at Phase 3 in unresectable hepatocellular carcinoma
October 21, 2019Research and Development, Sales and Marketing Cancer, Roche, immunotherapy, pharma, tecentriq
New Phase 3 data has emerged demonstrating the efficacy of Roche’s Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the …
AstraZeneca receives FDA approval for Farxiga
October 21, 2019Sales and Marketing
AstraZeneca have announced that the US FDA has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure …
GlaxoSmithKline sells two vaccines for up to £822m
October 21, 2019Sales and Marketing
GlaxoSmithKline has announced it will divest two of its major vaccines to Denmark-based Bavarian Nordic in a deal that will …
Medical cannabis: Growth by leaps and bounds
October 18, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Canada, Canopy Growth, medical cannabis, pharma
This article follows parts one and two of our trio of in-depth pieces focusing on the growing medical cannabis phenomenon. …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
